Drug
Aprepitant
Aprepitant: highest development phase Post-Market, developed by Heron Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Heron Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Aprepitant Injection NCT07639723 | Post-Market | PONV |
Latest
No recent events.
Follow Aprepitant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.